USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | - | - | $-0.96 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | - | - | $92.10M |
Guardant Health's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 12 | $-4.34 | $-5.18 | $-3.58 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 3 / 1 | $-3.34 | $-3.34 | $-3.19 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 14 | $474.71M | $453.90M | $508.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 4, 2022 | Mar 2022 | $-1.20 | - | - |
| Feb 23, 2022 | Dec 2021 | $-1.15 | $-0.89 | 22.61% |
| Nov 4, 2021 | Sep 2021 | $-0.89 | $-1.06 | -18.75% |
| Aug 5, 2021 | Jun 2021 | $-0.83 | $-0.96 | -15.11% |
| May 6, 2021 | Mar 2021 | $-0.83 | $-1.09 | -31.23% |
| Feb 24, 2021 | Dec 2020 | $-0.47 | $-0.94 | -99.11% |
| Nov 5, 2020 | Sep 2020 | $-0.36 | $-0.78 | -118.73% |
| Aug 6, 2020 | Jun 2020 | $-0.36 | $-0.57 | -58.20% |
| May 7, 2020 | Mar 2020 | $-0.39 | $-0.29 | 25.20% |
| Feb 24, 2020 | Dec 2019 | $-0.30 | $-0.27 | 11.27% |
| Nov 7, 2019 | Sep 2019 | $-0.37 | $-0.14 | 62.56% |
| Aug 6, 2019 | Jun 2019 | $-0.35 | $-0.13 | 62.84% |
| May 9, 2019 | Mar 2019 | $-0.37 | $-0.30 | 18.79% |
| Mar 12, 2019 | Dec 2018 | $-0.35 | $-0.30 | 14.94% |
| Nov 19, 2018 | Sep 2018 | $-0.29 | $-0.29 | 3.06% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 23, 2022 | Dec 2021 | $-4.26 | $-4.00 | - |
| Feb 24, 2021 | Dec 2020 | $-2.21 | $-2.58 | - |
| Feb 24, 2020 | Dec 2019 | $-0.88 | $-0.84 | - |
| Mar 12, 2019 | Dec 2018 | $-1.59 | $-0.59 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 4, 2022 | Mar 2022 | $106.15M | - | - |
| Feb 23, 2022 | Dec 2021 | $99.04M | $108.11M | 1.09% |
| Nov 4, 2021 | Sep 2021 | $92.64M | $94.78M | 1.02% |
| Aug 5, 2021 | Jun 2021 | $84.61M | $92.10M | 1.09% |
| May 6, 2021 | Mar 2021 | $78.67M | $78.67M | 1.00% |
| Feb 24, 2021 | Dec 2020 | $76.73M | $78.32M | 1.02% |
| Nov 5, 2020 | Sep 2020 | $65.93M | $74.57M | 1.13% |
| Aug 6, 2020 | Jun 2020 | $59.17M | $66.33M | 1.12% |
| May 7, 2020 | Mar 2020 | $56.47M | $67.51M | 1.20% |
| Feb 24, 2020 | Dec 2019 | $54.83M | $62.90M | 1.15% |
| Nov 7, 2019 | Sep 2019 | $45.42M | $60.85M | 1.34% |
| Aug 6, 2019 | Jun 2019 | $36.43M | $53.98M | 1.48% |
| May 9, 2019 | Mar 2019 | $31.65M | $36.66M | 1.16% |
| Mar 12, 2019 | Dec 2018 | $24.90M | $32.87M | 1.32% |
| Nov 19, 2018 | Sep 2018 | $17.50M | $21.69M | 1.24% |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 23, 2022 | Dec 2021 | $364.70M | $373.65M | 2.45% |
| Feb 24, 2021 | Dec 2020 | $284.84M | $286.73M | 0.66% |
| Feb 24, 2020 | Dec 2019 | $206.22M | $214.38M | 3.95% |
| Mar 12, 2019 | Dec 2018 | $81.67M | $90.64M | 10.98% |
GH's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.
Guardant Health's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.
Guardant Health's previous annual earnings date was Feb 23, 2022 for its fiscal year ended Dec 31, 2021.
GH's earnings per share (EPS) was $-4.00, beating the consensus analysts forecast of $-4.26 by -6.10% , and lower than the previous year's EPS (Dec 2020) by 55.04%.
Revenues were $373.65M, better than the forecast of $364.70M by 2.45%, and up by 30.32% from previous year's revenue.
The company reported a net income of $-405.67M.
Guardant Health reported a free cash flow of $-284.05M for its fiscal year, compared to $-157.99M a year ago.
The company ended the fiscal year with $1.37B in total debt, an increase of 68.99% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
